Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsMelphalanTransplantation, HomologousTransplantation ConditioningCombined Modality TherapyTreatment OutcomeRemission InductionStem CellsSalvage TherapyDisease-Free SurvivalEtoposideHodgkin DiseaseCyclophosphamideLymphoma, Non-HodgkinMyeloablative AgonistsCytarabineRecurrenceCarmustineSurvival RateHematopoietic Stem Cell MobilizationBone Marrow TransplantationGraft vs Host DiseaseThiotepaBone Marrow PurgingVincristineSurvival AnalysisHematologic NeoplasmsLymphoma, Mantle-CellWhole-Body IrradiationAmyloidosisRetrospective StudiesDoxorubicinHematopoietic Stem CellsBusulfanBoronic AcidsDexamethasonePrognosisPyrazinesGraft SurvivalAntibodies, Monoclonal, Murine-DerivedFollow-Up StudiesLymphoma, FollicularAntineoplastic Agents, AlkylatingAntigens, CD34AutograftsLymphoma, T-Cell, PeripheralLiver TransplantationThalidomideIfosfamideAntineoplastic AgentsInduction ChemotherapyMesenchymal Stem Cell TransplantationTime FactorsGranulocyte Colony-Stimulating FactorLeukapheresisPrednisoneLymphomaPodophyllotoxinLymphoma, Large B-Cell, DiffuseNeoplasm, ResidualTransplantation ChimeraMaintenance ChemotherapyTissue DonorsCord Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteCell TransplantationKidney TransplantationEnteropathy-Associated T-Cell LymphomaLymphoma, B-CellEmbryonic Stem CellsMyelodysplastic SyndromesMitoxantroneIdarubicinLeukemia, Plasma CellInfusions, SpinalNeoplasms, Second PrimaryCisplatinCarboplatinAdult Stem CellsProspective StudiesBlood Component RemovalChemotherapy, AdjuvantImmunosuppressive AgentsHistocompatibility TestingNeoplasm Recurrence, LocalAntibodies, MonoclonalFeasibility StudiesDrug Administration ScheduleLeukemia, MyeloidFatal OutcomeCell DifferentiationKeratins, Type IILife TablesHistocompatibilityNeutropenia